Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) - Total Liabilities
Based on the latest financial reports, Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) has total liabilities worth CN¥1.42 Billion CNY (≈ $208.32 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Shandong Jincheng Pharmaceutical and Che generate cash to assess how effectively this company generates cash.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Shandong Jincheng Pharmaceutical and Chemical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 300233 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Jincheng Pharmaceutical and Chemical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tangrenshen Group Co Ltd
SHE:002567
|
China | CN¥11.73 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩6.34 Billion |
|
MannKind Corp
NASDAQ:MNKD
|
USA | $539.19 Million |
|
Group Up Industrial Co Ltd
TWO:6664
|
Taiwan | NT$4.75 Billion |
|
Southside Bancshares, Inc.
NASDAQ:SBSI
|
USA | $7.55 Billion |
|
Aoyuan Beauty Valley Technology Co Ltd
SHE:000615
|
China | CN¥2.81 Billion |
|
Service Stream Ltd
AU:SSM
|
Australia | AU$533.37 Million |
|
KRN Heat Exchanger and Refrigeration
NSE:KRN
|
India | Rs2.00 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Shandong Jincheng Pharmaceutical and Chemical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300233 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Jincheng Pharmaceutical and Chemical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Jincheng Pharmaceutical and Chemical Co Ltd (2008–2024)
The table below shows the annual total liabilities of Shandong Jincheng Pharmaceutical and Chemical Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.77 Billion ≈ $259.42 Million |
-16.96% |
| 2023-12-31 | CN¥2.14 Billion ≈ $312.42 Million |
-1.47% |
| 2022-12-31 | CN¥2.17 Billion ≈ $317.07 Million |
+18.03% |
| 2021-12-31 | CN¥1.84 Billion ≈ $268.63 Million |
+19.76% |
| 2020-12-31 | CN¥1.53 Billion ≈ $224.30 Million |
+1.68% |
| 2019-12-31 | CN¥1.51 Billion ≈ $220.60 Million |
+25.78% |
| 2018-12-31 | CN¥1.20 Billion ≈ $175.39 Million |
+24.04% |
| 2017-12-31 | CN¥966.24 Million ≈ $141.39 Million |
+28.37% |
| 2016-12-31 | CN¥752.68 Million ≈ $110.14 Million |
+9.73% |
| 2015-12-31 | CN¥685.95 Million ≈ $100.38 Million |
+2.59% |
| 2014-12-31 | CN¥668.61 Million ≈ $97.84 Million |
+20.66% |
| 2013-12-31 | CN¥554.11 Million ≈ $81.08 Million |
+12.11% |
| 2012-12-31 | CN¥494.26 Million ≈ $72.33 Million |
+12.50% |
| 2011-12-31 | CN¥439.36 Million ≈ $64.29 Million |
-24.59% |
| 2010-12-31 | CN¥582.62 Million ≈ $85.26 Million |
+41.74% |
| 2009-12-31 | CN¥411.04 Million ≈ $60.15 Million |
+0.33% |
| 2008-12-31 | CN¥409.67 Million ≈ $59.95 Million |
-- |
About Shandong Jincheng Pharmaceutical and Chemical Co Ltd
Shandong Jincheng Pharmaceutical Group Co., Ltd researches and develops, produces, markets, and sells Cephalosporin intermediates in China and internationally. It offers medical intermediate, animal nutrition, health care, CMO, CDMO, pharmaceuticals, API, finished dosage, and fine chemicals. Shandong Jincheng Pharmaceutical Group Co., Ltd was founded in 2004 and is based in Zibo, China.